Abstract:Background: The increasing incidence of colorectal cancer is one of the most frequently addressed medical topics worldwide. It represents the third most commonly diagnosed cancer in both men and women globally, with significant implications for public health. Mortality for this type of malignancy remains high, second only to lung cancer. Given their clinical relevance, the identification and understanding of KRAS and BRAF mutations have become crucial components of personalized medicine approaches in colorectal cancer. Hence, our desire is to carry out a research that analyzes the impact of these mutations in terms of survival and mortality on patients diagnosed with colorectal cancer. Methods: We conducted a retrospective study spanning from 2018 to 2022, which involved 118 patients diagnosed with colorectal cancer. The patients were selected from the databases of the Oradea County Emergency Clinical Hospital and Pelican Oradea Hospital. Genetic testing was performed at the "Resident Laboratory" clinic. Subsequently, patients were divided into two groups of equal size based on the presence or absence of mutations. Results: The survival rate one year after the diagnosis of colorectal cancer is 84.74% (N=50/59) for the mutant group versus 67.96% (N=40/59) for the wild-type group. The survival rate at five years from the diagnosis of colorectal cancer is 25.93% (N=15/59) for patients with wild-type tumors compared to 33.54% (N=20/59) for patients with tumors with mutant status (p=0.483, HR=1.153, CI 95% 0.7661-1.735). The five-year survival rate, depending on the mutation present, highlights the fact that the average overall survival for those with the KRAS mutation is 38.6 months (CI 95% 35.22-41.97) and for those with the BRAF mutation is 8.3 months (CI 95% 5.42-11.17) (p=0.039). The mortality rate for mutant KRAS is 44.89% (N=22/50), while for those with mutant BRAF, it is 100% (N=6/6). Conclusions: We observed no statistically significant difference in overall survival rate and disease-free interval between the two studied groups, but the overall survival was better for those with mutations present (38.64 months versus 31.07 months for wild-type tumors). The mortality rate is higher among tumors with wild-type status (p=0.005), in the first year after the diagnosis of colorectal cancer. The BRAF mutation confers a much worse prognosis than the KRAS mutation, from both the survival analysis and the mortality rate.

The impact of RAS mutation on the treatment strategy of colorectal cancer

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers

Advances in KRAS mutation inhibition in metastatic colorectal cancer

A Retrospective Study from Romania

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Current therapy of advanced colorectal cancer according to RAS/RAF mutational status

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

KRAS, a New Target for Precision Medicine in Colorectal Cancer?

KRAS Mutation Testing in Metastatic Colorectal Cancer.

New Arrows in the Quiver

Genetic Profiling and Survival Outcomes in Romanian Colorectal Cancer Patients

KRAS in NSCLC: State of the Art and Future Perspectives

Targeting KRAS in Colorectal Cancer

Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer

Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma

KRAS mutation: from undruggable to druggable in cancer

Assessment of KRASG12C inhibitors for colorectal cancer

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives